SLC8B1抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse placenta tissue lysate, Primary antibody: P05297(SLC8B1 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P05297(SLC8B1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The solute carrier family 8 member B1 (SLC8B1), also known as the mitochondrial sodium-calcium exchanger (NCLX), is a critical transporter protein localized to the inner mitochondrial membrane. It facilitates the exchange of sodium (Na⁺) and calcium (Ca²⁺) ions across the mitochondrial membrane, playing a pivotal role in regulating mitochondrial Ca²⁺ homeostasis. This process is essential for maintaining cellular energy production, calcium signaling, and apoptosis regulation. Dysregulation of SLC8B1/NCLX has been implicated in various pathological conditions, including neurodegenerative diseases (e.g., Parkinson’s disease), cardiac disorders (e.g., ischemia-reperfusion injury), and cancer.

SLC8B1 antibodies are immunological tools designed to detect and quantify the expression, localization, and functional dynamics of the NCLX protein in research settings. These antibodies are widely utilized in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to study mitochondrial calcium handling in both physiological and disease contexts. Their specificity and reliability are critical for elucidating the molecular mechanisms linking mitochondrial Ca²⁺ dysregulation to cellular dysfunction. Recent studies have highlighted SLC8B1/NCLX as a potential therapeutic target, driving the development and validation of high-affinity antibodies for preclinical investigations. Researchers prioritize antibodies with cross-reactivity validated across species (e.g., human, mouse) to ensure translational relevance in disease models.